TY - JOUR
T1 - Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP
AU - Driessen, Julia
AU - Kersten, Marie José
AU - Visser, Lydia
AU - van den Berg, Anke
AU - Tonino, Sanne H.
AU - Zijlstra, Josée M.
AU - Lugtenburg, Pieternella J.
AU - Morschhauser, Franck
AU - Hutchings, Martin
AU - Amorim, Sandy
AU - Gastinne, Thomas
AU - Nijland, Marcel
AU - Zwezerijnen, Gerben J. C.
AU - Boellaard, Ronald
AU - de Vet, Henrica C. W.
AU - Arens, Anne I. J.
AU - Valkema, Roelf
AU - Liu, Roberto D. K.
AU - On behalf of the HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC)
AU - Drees, Esther E. E.
AU - de Jong, Daphne
AU - Plattel, Wouter J.
AU - Diepstra, Arjan
N1 - Funding Information: We would like to dedicate this article to the memory of Professor Anton Hagenbeek, who together with MJK initiated this study. The authors would like to thank all patients who participated in the trial, the Transplant BRaVE-trial team of the Trial Office of the Amsterdam UMC, location AMC for their efforts in trial management and central data management, and the members of the Data Safety and Monitoring Board. The authors thank Marjolein Spiering, Edith van Dijkman, the data managers, trial nurses, lab- and pharmacy personnel for their essential assistance with collecting and managing the study data. The authors thank Nathalie Hijmering, HOVON Pathology Facility and Biobank, for biopsy collection and support of central pathology review. Funding Information: This work was supported by research funding from Takeda. Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/12
Y1 - 2022/12
N2 - Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall survival was 95% (90–100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.
AB - Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall survival was 95% (90–100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.
UR - http://www.scopus.com/inward/record.url?scp=85140062604&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41375-022-01717-8
DO - https://doi.org/10.1038/s41375-022-01717-8
M3 - Article
C2 - 36241696
SN - 0887-6924
VL - 36
SP - 2853
EP - 2862
JO - Leukemia
JF - Leukemia
IS - 12
ER -